"Designing Growth Strategies is in our DNA"
The Canada sexually transmitted disease testing market size was valued at USD 205.9 million in 2021. The market is projected to grow from USD 233.6 million in 2022 to USD 310.5 million by 2029, exhibiting a CAGR of 4.1% during the forecast period. The global COVID-19 pandemic has been unprecedented and staggering, with sexually transmitted disease testing experiencing lower-than-anticipated demand across Canada compared to pre-pandemic levels. Based on our analysis, the Canada sexually transmitted disease testing market exhibited a decline of -12.5% in 2020 as compared to 2019.
Sexually Transmitted Diseases (STDs) spread from one person to another through sexual intercourse, whereas some diseases, such as herpes and HPV, can spread through physical contact and skin-to-skin contact. Sexually transmitted diseases, in many cases do not show any symptoms but they can later cause serious health issues. The diagnosis for STDs can be done through blood, urine, and other body fluids sample testing.
There is increasing prevalence of Sexually Transmitted Infections (STI) such as chlamydia, HIV/AIDS, and HPV. Growing government initiatives toward increasing patient awareness about sexual health and sexually transmitted disease diagnosis are expected to boost the Canada sexually transmitted disease testing market growth.
Market Growth was Hampered Due to Decline in Demand and Supply Chain Disruptions
The emergence of COVID-19 had a negative impact on the Canada sexually transmitted diseases testing market growth. The negative impact was due to lockdown restrictions and shift of resources to control the spread of COVID-19. The Canada sexually transmitting disease testing market witnessed a decline in its growth by -12.5% in 2020 compared to the previous year.
The STD diagnosis being performed at different locations of testing, such as diagnostic centers and hospitals, declined after the COVID-19 outbreak as the resources were shifted to control the spread of COVID-19. This led to the decline in the number of STD cases being tested which increased the undiagnosed population across Canada.
Moreover, due to decrease in demand for sexually transmitted disease testing kits and supply chain disruptions, the sales of STD diagnostics decreased in 2020. Many market players experienced a decline in their revenues during COVID-19 pandemic.
However, the market experienced significant recovery in 2021 and is expected to fully recover by 2022 due to rise in the number of untreated patient population of sexually transmitted diseases during the pandemic.
Request a Free sample to learn more about this report.
Shift to Point-of-Care Testing for STDs to Contribute to Market Growth
One of the most critical trend in the sexually transmitted disease testing industry is the increasing shift of patient population toward point-of care testing from laboratory testing. STD diagnosis plays a key role in disease treatment and prevention of the spread of the infection from person to person.
Due to increased prevalence of STDs in the country, the government has increased its focus on creating awareness regarding the disease. Moreover, the government is also focusing on increasing the STD diagnosis rate across the country. Furthermore, the government has also been conducting research to study the efficiency of certain diagnostics for infectious diseases.
Additionally, point-of-care testing is performed at various locations such as hospitals, physicians’ offices, and clinics due to various advantages associated with this diagnosis over laboratory testing. These advantages include patient mobility and time-efficient processes to get early result reports.
Therefore, various advantages associated with the point-of-care testing are expected to strengthen the market growth in the near future.
Rising Incidence of STDs to Drive the Market Growth
The growing incidence of sexually transmitted diseases among the Canadian population is expected to accelerate the demand for sexually transmitted disease testing.
Moreover, the increasing initiatives by market players to launch diagnostic kits and tests are anticipated to contribute to the market growth during the forecast period.
Whereas, lack of awareness in the Canadian population about the safer sexual intercourse process and inappropriate sharing of contaminated personal objects, such as used syringes and other personal belongings, are expected to increase the incidences of STDs among the population.
Such increasing incidences of STDs and the launch of new products by major market players are expected to boost the market across the country.
Government Initiatives to Increase Awareness about STI Testing and Sexual Health to Boost the Market
The increasing prevalence of STDs and a considerable number of untreated patient population have increased the focus of the government of Canada on spreading awareness about the detection and diagnosis of sexually transmitted diseases across the country.
Moreover, the Canadian AIDS Treatment Information Exchange (CATIE) stated three strategies for the prevention of sexual transmission of HIV such as appropriate use of condom, use of oral Pre-exposure Prophylaxis (PrEP), and Antiretroviral Treatment (ART) to maintain an undetectable viral load of people coming in contact with the HIV infected patient population.
Hence, such increasing government initiatives for creating awareness about STDs have increased the number of STD testing in the country.
Reluctance toward STD Testing to Limit the Market Growth
Despite various initiatives taken by the government for spreading awareness to control the spread of sexually transmitted disease in Canada, significant number of the patient population still avoid STD testing. Hence, this factor has been restricting the market growth.
Certain factors limiting the adoption of sexually transmitted disease testing in the country include the stigma associated with sexual health and sexually transmitted disease, lack of awareness among the population, and limited availability of resources for counseling about sexual health. Additionally, treatment structure and time-consuming operations have also been restricting the patient population from getting a diagnosis and the treatment for sexually transmitted diseases.
Increasing Incidence of Sexually Transmitted Infections to Accelerate the Growth of Reagents & Kits Segment
On the basis of product, the market is segmented into instruments and reagents & kits.
The reagents & kits segment accounted for a major share of the market in 2021 and is estimated to hold a significant market share throughout the forecast period. The growth of the segment is attributed to the rising incidence of sexually transmitted diseases in Canada and increasing use of these reagents and kits in the diagnostic procedures.
However, the instruments segment is expected to grow at a substantial CAGR during the forecast period. The segmental growth is due to the rising focus of the government toward the awareness of sexually transmitted disease testing and increased installation of these instruments in hospitals and diagnostic centers.
Increasing Number of Patients Opting for Laboratory Testing to Favor Growth
Based on setting, the market is bifurcated into laboratory testing and Point-of-Care (POC). The laboratory testing segment accounted for the maximum market share in 2021. High growth of the segment is attributed to the rising patient footfall in independent clinical laboratories for testing of STDs.
However, the point-of-care segment is estimated to have the fastest CAGR during the forecast period. The growth of the segment is attributed to the benefits offered by point-of-care testing over laboratory testing. Moreover, increasing focus of market players toward the introduction of point-of-care testing kits for the diagnosis of sexually transmitted infections is expected to boost the segmental growth.
To know how our report can help streamline your business, Speak to Analyst
Increasing Incidences of Chlamydia to Boost the Demand for Testing During the Forecast Period
Based on application, the market is segmented into chlamydia, syphilis, genital herpes, gonorrhea, human immunodeficiency virus, Human Papillomavirus (HPV), and others. The chlamydia segment is anticipated to dominate the market throughout the forecast period owing to increasing incidences of chlamydia and rising number of patient admissions in hospitals for chlamydia testing.
Moreover, the syphilis segment is expected to grow at a significant CAGR during the forecast period. An increasing number of Canadian population getting infected with syphilis is expected to contribute to the highest growth of the segment during the forecast period.
Increasing Visits of the Patients in Independent Clinical Laboratories to Favor the Segmental Growth
On the basis of end-user, the market is segmented into independent clinical laboratories, homecare settings, hospital-based laboratories, and others. The independent clinical laboratories segment is anticipated to register lucrative growth during the forecast period due to factors such as growing number of patient visits to independent clinical laboratories in Canada and strong presence of these laboratories in the country.
The homecare settings segment is expected to expand at the highest CAGR during the forecast period. The increasing focus of market players toward the launch of self-tests for the diagnosis of STDs in Canada is expected to enhance the segment growth during the forecast period.
Comprehensive Product Offerings and Strong Distribution Channels to Strengthen the Growth of Market
The competitive landscape of the market is consolidated in nature. The key players operating in the market, such as F. Hoffmann-La Roche Ltd. and Hologic, Inc, accounted for the significant Canada sexually transmitted disease testing market share.
F. Hoffmann-La Roche Ltd. is a dominant market player due to the company’s strong distribution channel and versatile product offerings of kits & reagents for sexually transmitted disease testing. For instance, in May 2022, F. Hoffmann-La Roche Ltd. expanded its diagnostic capacity through its global access program and raised global funds to fight AIDS, tuberculosis, and malaria in the low-and middle-income countries which are facing higher issues of these diseases.
Whereas, other significant players include Cepheid (Danaher) and Bio-Rad Laboratories Inc. These companies accounted for substantial market share and is expected to gain more market share during the forecast period. This is attributed to increasing strategic initiatives such as new product launches and increasing distributors across the country.
An Infographic Representation of Canada Sexually Transmitted Disease Testing Market
To get information on various segments, share your queries with us
The research report provides a detailed competitive landscape. It focuses on key aspects such as major companies, product, setting, application, and end-users. Additionally, it offers insights into the market trends and impact of COVID-19. In addition to the factors mentioned above, the report encompasses several factors that have contributed to the growth of the market in the recent years.
ATTRIBUTE | DETAILS |
Study Period | 2015-2029 |
Base Year | 2021 |
Estimated Year | 2022 |
Forecast Period | 2022-2029 |
Historical Period | 2015-2020 |
Unit | Value (USD Million) |
Segmentation | By Product
|
By Setting
| |
By Application
| |
By End-user
|
Fortune Business Insights says that the Canada market stood at USD 205.9 million in 2021 and is projected to reach USD 310.5 million by 2029.
The market is expected to exhibit a CAGR of 4.1% during the forecast period (2022-2029).
By product, the reagents & kits segment is set to lead the market.
Increasing incidences of STDs, rising focus of major players for the introduction of products, and shift in preference toward point-of-care testing from laboratory testing in Canada to strongly drive the market growth.
F. Hoffmann-La Roche Ltd. and Hologic, Inc. are the top players in the market.